Business Wire

GN-HEARING

18.8.2020 09:02:06 CEST | Business Wire | Press release

Share
ReSound ONE: an entirely new class of hearing aids that offers a truly individualized hearing experience and the best sound quality for every user

GN Hearing, the global leader in hearing aid innovation, today unveils ReSound ONETM , a revolutionary new hearing aid* that solves one of the most enduring challenges for people with hearing loss. This unique solution places an additional microphone inside the ear canal, for the first time, allowing people relying on hearing aids to experience the world with their own ears while preserving the comfort of an open-fit device. Now every user can enjoy the benefits of superior sound quality and hear conversations better in noisy environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200818005077/en/

With its Organic Hearing philosophy, GN has always taken its design inspiration from how humans hear naturally and seeks to mimic this within its technology as closely as possible. Following this approach, ReSound ONE uniquely adapts to the needs and lifestyle of every individual rather than the other way around.

The outer ear (pinna) is designed by nature to work like an acoustic antenna. It helps the brain localize and tune in to a particular sound, for example when listening to a specific voice in a crowded café. However, the most popular styles of hearing aids (Receiver-In-Ear and Behind-The-Ear models) capture sound from microphones that sit behind the ear and then approximate the effect of the pinna. The result is an averaged and incomplete reproduction of sound, making it hard for the brain to achieve its natural localization and noise-cancelling function. In fact, of the 79 million people who wear hearing aids globally,1 93% report having trouble hearing in noisy environments and 55% get confused about where sounds come from.2

ReSound ONE is the world’s first full-featured* hearing aid with a Microphone & Receiver-In-Ear design (M&RIE) that uses the unique shape of every individual’s ear to collect sound. This remarkable innovation has been achieved with a radical new receiver system combined with all-new Digital Feedback Suppression (DFS Ultra III), enabled by GN’s new and most powerful sound-processing chipset ever. By picking up sound directly inside the ear, ReSound ONE gives the brain everything it needs to tune in to individual voices, as well as significantly reducing background noise. Clinical studies show that all hearing aid users benefit from listening to sounds collected with their own ears, with 90% of users preferring the sound quality of ReSound ONE with M&RIE instead of only the microphone behind the ear.3,4

GN Hearing CEO and President, Gitte Aabo explains, “I am very proud that, once again, GN is first in the industry with ground-breaking innovation that will make a genuine difference in how people experience conversations and sounds around them. Placing a microphone into the ear with an open-fit hearing aid is something the industry has battled for many years to achieve. This technology will allow people with hearing loss to feel that they are literally getting their own hearing back and hearing the way nature intended. ReSound ONE will boost the communication, relationships, and confidence of every individual.”

Additionally, ReSound ONE incorporates new All Access Directionality and the user-activated Ultra Focus settings. These enhanced operating modes significantly improve speech recognition while preserving spatial perception in complex sound and noise situations. ReSound ONE includes unmatched rechargeability and extensive connectivity options to both iOS and Android™ smartphones for streaming and hearing aid control.

ReSound ONE is available from August 27, 2020 in rechargeable and non-rechargeable models. This technology is also available in new Beltone Imagine hearing aids.

For further information, visit the ReSound Newsroom and read more about the Organic Hearing philosophy.

Learn more about GN’s 2020 and beyond strategy with focus on individualized customer experiences.

- ENDS –

NOTES TO EDITORS

About ReSound

ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The introduction of this new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.

About GN Group

The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.

150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).

​​Visit our homepage GN.com, get to know our innovation and leadership​ ​​, and connect with us on LinkedIn , Facebook and Twitter .

*ReSound ONE introduces the world’s first full-featured hearing aid with M&RIE for a truly individualized, more complete sound experience. Full-featured means a microphone in the ear and two additional, standard directional microphones, directionality features and wireless audio streaming.

© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.

References

  1. World Health Organization (2020) Deafness and hearing loss. Factsheet. https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss . Accessed: July, 2020
  2. MarkeTrak 2019
  3. Jespersen et al (2020): M&RIE receiver preferred for sound quality and localization. ReSound white paper
  4. Groth J. (2020). An innovative RIE with microphone in the ear lets users “hear with their own ears”. ReSound white paper

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye